AICAR Research: Endurance, AMPK Data & What the Studies Show
AICAR is a synthetic cell-permeable nucleoside and a direct activator of AMPK, the body's master metabolic regulator. Nicknamed the 'exercise mimetic', its literature spans cell assays, subcutaneous animal endurance trials, neuro-immunology models and human cardiac surgery data.
Mechanism of action
AICAR (5-Aminoimidazole-4-carboxamide ribonucleoside) is a synthetic, cell-permeable nucleoside, not a peptide. Once inside the cell it is phosphorylated to ZMP, which mimics AMP.
That AMP mimicry directly activates AMPK (AMP-activated protein kinase) — the sensor that switches on when cells are energy-starved or under intense exercise, driving fat oxidation, glucose uptake and mitochondrial adaptation.
Because AICAR triggers this state chemically, it reproduces several downstream signatures of endurance training without physical exertion — the basis for the 'exercise mimetic' or 'couch potato pill' label used in sports medicine literature.
The studies
Each study below states the benefit that was tested, then what the data showed. Note the split: metabolic and endurance findings come from cell and animal work, while the strongest human dataset is cardiac surgery, not fat loss or performance.
Metabolism
In vitro cellular glucose and fat metabolism
Benefit tested: can AICAR bypass hormonal signalling to force cells to absorb glucose, stop building fat and start burning lipid?
Differentiated 3T3-L1 adipocytes and skeletal muscle cells treated directly with AICAR in culture · glucose transport, lipogenesis and lipolysis endpoints
- Blocked
- Acetyl-CoA carboxylase
- Sharply increased
- GLUT4 glucose transport
- Bypassed
- Insulin requirement
the fat-building enzyme
Benefits shown in the data
- Directly blocked acetyl-CoA carboxylase, the enzyme responsible for building new body fat.
- Triggered a large increase in GLUT4 glucose transport proteins, forcing cells to take up sugar.
- Shifted cells toward burning fat as fuel independently of insulin, establishing the mechanistic case for type 2 diabetes research.
- This is an isolated cell assay — concentrations and exposure in a dish do not translate directly to a living organism.
- Insulin-independent glucose uptake is the key finding, since it suggests activity even where insulin signalling is impaired.
- Clinical metabolic benefit in humans has not been established from this work.
Performance & endurance
'Exercise mimetic' and endurance supercharging
Benefit tested: can daily AICAR injections increase running endurance and remodel muscle fibre type in sedentary subjects with no training?
Adult animal models · daily subcutaneous AICAR injections · 4 weeks · no exercise training · running endurance, time-to-exhaustion and muscle gene expression
- +44%
- Running endurance
- Shifted to slow-twitch
- Muscle fibre composition
- Up-regulated
- Oxidative metabolism genes
vs untreated controls
Benefits shown in the data
- Increased running endurance and time-to-exhaustion by 44% in sedentary subjects that never trained.
- Triggered mitochondrial biogenesis — the creation of new cellular energy factories.
- Shifted muscle composition toward fatigue-resistant slow-twitch fibres and up-regulated oxidative metabolism genes.
- This is the landmark result behind the 'exercise in a syringe' framing — but it is animal data over a 4-week dosing course.
- The effect was produced without any exercise, which is precisely why anti-doping bodies took interest.
- Comparable controlled endurance data in humans does not exist.
Neuro-immunology
Neuro-protection and halting multiple sclerosis progression
Benefit tested: can AICAR switch off CNS inflammation and protect myelin in the standard animal model of multiple sclerosis?
Animal models with experimental autoimmune encephalomyelitis (EAE) · subcutaneous AICAR treatment protocol · clinical severity, CNS immune infiltration and demyelination endpoints
- Significantly attenuated
- Clinical disease severity
- Blocked
- CNS inflammatory infiltration
- Prevented
- Demyelination
Benefits shown in the data
- Significantly reduced the clinical severity of the neurodegenerative disease model.
- Blocked infiltration of inflammatory immune cells into the central nervous system.
- Stabilised the blood-brain barrier and prevented demyelination of neuronal myelin sheaths.
- EAE is the standard animal proxy for MS, but many compounds that work in EAE fail in human trials.
- The mechanism is AMPK-driven suppression of inflammatory cytokine signalling rather than direct myelin repair.
- No human MS data supports AICAR use.
Human clinical data
Human cardioprotection trials (the ischemia reset)
Benefit tested: can IV AICAR infused before cardiac surgery condition heart muscle to resist ischemic injury and tissue death?
Patients undergoing coronary artery bypass graft (CABG) surgery · intravenous AICAR versus placebo · post-operative myocardial infarction and cardiac injury endpoints
- ~4× lower
- Post-op myocardial infarction
- Intravenous infusion
- Route
- Direct AMPK activation
- Mechanism
vs placebo
Benefits shown in the data
- Reduced the incidence of post-operative myocardial infarction by nearly four-fold compared with placebo.
- Demonstrated that human cardiac tissue responds strongly to direct AMPK activation.
- Guarded heart cells against injury when oxygen supply crashed during surgery.
- This is the strongest human dataset for AICAR — and it is about surgical cardioprotection, not fat loss or athletic performance.
- Delivery was intravenous infusion in a controlled hospital setting, immediately before a defined ischemic event.
- Nothing in this trial supports AICAR use for body composition or endurance in humans.
Storage & handling
AICAR is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until fully dissolved and never shake.
Store reconstituted solution at 2-8 °C, protect from light, and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
AICAR research context
AICAR's performance data is pronounced enough to place it on the WADA prohibited list. The metabolic and endurance findings most often discussed come from cell and animal work, while the strongest human dataset is the cardiac surgery trial summarised above.
WADA prohibited — Section S4
The World Anti-Doping Agency lists AICAR under Section S4 (Hormone and Metabolic Modulators). Anti-doping tests can detect synthetic AICAR against natural background levels, so competing athletes should expect sanction if detected.
Endurance data is from animal models
The headline 44% endurance figure comes from a 4-week subcutaneous dosing study in animal models. There is no equivalent controlled human trial demonstrating endurance or fat-loss benefit at tolerable doses.
AMPK activation is systemic
AMPK sits upstream of growth, autophagy and cell-survival pathways in every tissue. Chronic pharmacological activation is an active research area; long-term safety in humans has not been established.
Research use only
AICAR is not an approved therapy for diabetes, obesity, multiple sclerosis or performance enhancement in South Africa or most jurisdictions. Material supplied here is strictly for laboratory research and is not for human or veterinary use.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.